Ubenimex

乌苯美司

Report date: 2023/02/27 09:47:28
NME

Base Information

Drug NameUbenimex
Drug Alias NameUbestatin乌本美司BestatinNSC-265489NK-421 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunostimulantsLeukotriene A-4 hydrolase inhibitorsAminopeptidase B inhibitors
TargetsAminopeptidase BLeukotriene A-4 hydrolase
Therapy Area/IndicationsLymphedemaPulmonary Arterial HypertensionLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsLeukemia, Myeloid, AcuteNeoplasms
Approved Indications in ChinaNeoplasms
Original Approved Country/TerritoryJapan
Original Approved Date1987/06/01
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNippon Kayaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNippon Kayaku Co LtdZhejiang Apeloa Kangyu Pharmaceutical Co Ltd
Inactive CompaniesEiger Biopharmaceuticals Inc
Active IndicationsLeukemia, Myeloid, AcuteNeoplasms
Inactive IndicationsLymphedemaPulmonary Arterial Hypertension

Other Information

ATC CodeL01X
Related LinksWikipediaKEGG